Institute for Neurodegenerative Diseases and Departments of Neurology and Bioengineering and Therapeutic Sciences, University of California San Francisco Schools of Medicine and Pharmacy, San Francisco, CA 94143, USA.
Sci Transl Med. 2010 May 5;2(30):30cm16. doi: 10.1126/scitranslmed.3000169.
Academic labs have been responsible for virtually all of the basic science discoveries that translate into the discovery and development of innovative new medicines. There is a growing concern that large pharmaceutical and biotechnology companies are not able to sustain research pipelines that bring new compounds into drug development that translate into innovative new medicines, especially in areas with high unmet medical need. To address the needs of patients, caregivers, and society, academic labs have played and can continue to play an important role at one or more stages in the development of innovative medicines, both directly and through collaborations with researchers in pharmaceutical and biotechnology companies. Collaboration is in the best interests of patients and society if it accelerates the translation of basic science discoveries to new medicines that address unmet medical needs.
学术实验室负责几乎所有将基础科学发现转化为创新新药发现和开发的工作。人们越来越担心，大型制药和生物技术公司无法维持将新化合物推进药物开发的研究管道，这些化合物可以转化为创新的新药，特别是在高未满足医疗需求的领域。为了满足患者、护理人员和社会的需求，学术实验室在创新药物的开发的一个或多个阶段都发挥了作用，并可以继续发挥重要作用，无论是直接参与还是与制药和生物技术公司的研究人员合作。如果合作能够加速将基础科学发现转化为解决未满足医疗需求的新药，那么它符合患者和社会的最佳利益。
